Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc expected to post a loss of 13 cents a share - Earnings Preview

* Abcellera Biologics Inc  ABCL.OQ   ABCL.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Vancouver British Columbia-based  company is expected
to
report  a 88.3% decrease in revenue to $11.905 million from
$101.38 million a year ago, according to the mean estimate from
8 analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Abcellera Biologics
Inc
is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $24.5​, above​ its last closing price of $4.11.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.13      -0.11     Beat    15.4
 Mar. 31 2023  -0.12       -0.14      -0.14     Met     -3.2
 Dec. 31 2022  0.00        -0.01      -0.10     Missed  -1,804
                                                        .8​
 Sep. 30 2022  0.05        0.05       0.08      Beat    76.1
 ​​Jun.        -0.01       -0.02      -0.02     Met     -28.5
 30 2022                                                
 Mar. 31 2022  0.40        0.38       0.54      Beat    40.6​
 Dec. 31 2021  0.18        0.19       0.19      Met     0.6
 Sep. 30 2021  -0.07       -0.05      -0.08     Missed  -52.4
 This summary was machine generated November 1 at 02:40 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on AbCellera Biologics

See all news